Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia
KJ Maddocks, AS Ruppert, G Lozanski… - JAMA …, 2015 - jamanetwork.com
Importance The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with
chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy with this drug and
outcomes following discontinuation have not been evaluated outside of clinical trials with
relatively short follow-up. Objective To determine features associated with discontinuation of
ibrutinib therapy and outcomes. Design, Setting, and Participants A total of 308 patients
participating in 4 sequential trials of ibrutinib at The Ohio State University Comprehensive …
chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy with this drug and
outcomes following discontinuation have not been evaluated outside of clinical trials with
relatively short follow-up. Objective To determine features associated with discontinuation of
ibrutinib therapy and outcomes. Design, Setting, and Participants A total of 308 patients
participating in 4 sequential trials of ibrutinib at The Ohio State University Comprehensive …
